Multidisciplinary Management of Metastatic Pancreatic Neuroendocrine Tumor Using a Combination of Beta, Alpha Radionuclide and Ethanol Ablation Therapies.

Clin Nucl MedApr 21, 2026 (epub)

Piyush Aggarwal, Sahaj Rathi, Ashwani Sood et al.

✦ AI-curated · Sources linked

Case in brief

A young patient with metastatic pancreatic neuroendocrine tumor underwent peptide receptor radionuclide therapy (PRRT) using beta and alpha radionuclides. Following this treatment, endoscopic ultrasound (EUS)-guided ethanol ablation was performed on residual metastatic lymph nodes, resulting in a complete response. This case highlights the potential of combining systemic and local therapies for improved outcomes.

Diagnostic / clinical pearl

Combining endoscopic ultrasound-guided ethanol ablation with radionuclide therapy may enhance treatment efficacy in metastatic neuroendocrine tumors.

Why it matters

This case underscores the importance of considering local therapies in conjunction with systemic treatments, particularly in younger patients with longer life expectancies.

Source

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.